A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia-Reference-Cited by-同舟云学术

A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia

Published:2023-01 Issue:1 Volume:61 Page:106699
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Gatti Milo^ORCID,Pascale Renato,Cojutti Pier Giorgio,Rinaldi Matteo,Ambretti Simone,Conti Matteo^ORCID,Tedeschi Sara,Giannella Maddalena,Viale Pierluigi,Pea Federico^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference23 articles.

1. Antimicrobial Resistance;Marston;JAMA,2016

2. New β-lactam-β-lactamase inhibitor combinations;Yahav;Clin Microbiol Rev,2020

3. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: A systematic literature review;Soriano;Infect Dis Ther,2021

4. Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections;Gatti;Curr Opin Infect Dis,2021

5. Pharmacokinetics and pharmacodynamics of β-lactamase inhibitors;Crass;Pharmacotherapy,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

2. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

3. Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort;Antibiotics;2024-07-02

4. The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study;Journal of Antimicrobial Chemotherapy;2024-02-15

5. Ceftazidime-avibactam induced renal disorders: past and present;Frontiers in Pharmacology;2024-01-22